Product Description
Daewon is developing Pelubiprofen as a treatment for degenerative joint disease. (Sourced from: https://www.daewonpharm.com/eng/rnd/sub05_01.jsp?mb=03&mm=35&ms=351&lang=1)
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea | Russia
Approved Indications: None
Known Adverse Events: None
Company: Daewon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Chronic Pain|Arthritis, Rheumatoid|Back Pain|Respiratory Tract Infections|Injuries/wounds Unspecified|Other
Phase 1: Healthy Volunteers|Osteoarthritis|Respiratory Tract Infections|Arthritis, Rheumatoid|Acute Pain|Back Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DW9801-303 | P3 |
Unknown status |
Other |
2021-08-30 |
59% |
| DW1809-102 | P1 |
Completed |
Respiratory Tract Infections|Acute Pain|Arthritis, Rheumatoid|Back Pain|Osteoarthritis |
2020-09-08 |
45% |
| DW1809-103 | P1 |
Completed |
Osteoarthritis|Arthritis, Rheumatoid|Respiratory Tract Infections|Acute Pain|Back Pain |
2020-09-07 |
45% |
| DW9801-302 | P3 |
Unknown status |
Injuries/wounds Unspecified |
2019-12-31 |
60% |